// App-Quantinova.ai

TPS3656 : An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001.

Researchers

Presenter

  • Randeep S. Sangha

Principal Investigators

  • Laurie Helen Sehn

  • John Kuruvilla

  • Michael Weickert

  • John Robert Mackey

  • Luc G. Berthiaume

Medical Centers

  • Cross Cancer Institute, Edmonton, AB, Canada

  • British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Pacylex Pharmaceuticals, Inc., Edmonton, AB, Canada

  • University of Alberta, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved